Advertisement

Medical Oncology

, 32:64 | Cite as

Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study

  • Tongchun Xue
  • Fan Le
  • Rongxin Chen
  • Xiaoying Xie
  • Lan Zhang
  • Ningling Ge
  • Yi Chen
  • Yanhong Wang
  • Boheng Zhang
  • Shenglong Ye
  • Zhenggang Ren
Original Paper

Abstract

Patients with huge hepatocellular carcinoma >10 cm in diameter represent a special subgroup for treatment. To date, there are few data and little consensus on treatment strategies for huge hepatocellular carcinoma. In this study, we summarized the effects and safety of transarterial chemoembolization for huge hepatocellular carcinoma. A retrospective study was performed based on a large cohort of patients (n = 511) with huge hepatocellular carcinoma who underwent serial transarterial chemoembolization between January 2008 to December 2011 and were followed up until March 2013. We found median survival time was 6.5 months. On multivariate analysis, Child-Pugh class (A versus B) (p < 0.0001), alpha-fetoprotein (≤400 µg/L) (p = 0.002), Barcelona Clinic Liver Cancer stage (B versus C) (p = 0.013), and other treatments after transarterial chemoembolization such as surgical resection (p = 0.008), radiation (p = 0.018), and local radiofrequency ablation (p = 0.002) were factors significantly associated with better overall patient survival after chemoembolization. Twenty-nine percent of these patients showed a tumor response after serial transarterial chemoembolization. Severe complications were few (4.9 %), including oncolytic syndrome (n = 3), tumor rupture (n = 3), gastrointestinal bleeding (n = 4), deep venous thrombosis (n = 3), acute cholecystitis (n = 4), femoral artery pseudoaneurysm (n = 1), acute pancreatitis (n = 1), and acute hepatic failure (n = 6). In conclusion, transarterial chemoembolization is a safe and effective treatment for selected patients with huge hepatocellular carcinoma and is recommended as a component of combination therapy. In addition, patients with good liver function and low alpha-fetoprotein levels may acquire greater survival benefits from transarterial chemoembolization.

Keywords

Chemoembolization Cohort studies Hepatocellular carcinoma 

Notes

Acknowledgments

This study was supported by the National Clinical Key Special Subject of China, the National Natural Science Foundation of China (81172275 and 21272565), and the National Basic Research Program of China (973 Program, 2009CB521700).

Conflict of interest

None.

Supplementary material

12032_2015_504_MOESM1_ESM.doc (34 kb)
Supplementary material 1 (DOC 33 kb)
12032_2015_504_MOESM2_ESM.doc (28 kb)
Supplementary material 2 (DOC 28 kb)

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Earl TM, Chapman WC. Tumor size remains key for prediction of hepatocellular carcinoma recurrence after liver transplantation. Ann Surg Oncol. 2011;18:1217–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Kim SJ, Lee KK, Kim DG. Tumor size predicts the biological behavior and influence of operative modalities in hepatocellular carcinoma. Hepatogastroenterology. 2010;57:121–6.PubMedGoogle Scholar
  4. 4.
    Jin YJ, Lee JW, Choi YJ, Chung HJ, Kim YS, Lee KY et al. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg. 2014;18:555–61.Google Scholar
  5. 5.
    Liang HY, Lu LG, Hu BS, Li Y, Shao PJ. Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas. Chin Med J (Engl). 2013;126:4270–6.PubMedGoogle Scholar
  6. 6.
    Ariizumi S, Kotera Y, Takahashi Y, Katagiri S, Yamamoto M. Impact of hepatectomy for huge solitary hepatocellular carcinoma. J Surg Oncol. 2013;107:408–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Yamashita Y, Taketomi A, Shirabe K, Aishima S, Tsuijita E, Morita K, et al. Outcomes of hepatic resection for huge hepatocellular carcinoma (>/=10 cm in diameter). J Surg Oncol. 2011;104:292–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg. 2002;194:592–602.CrossRefPubMedGoogle Scholar
  9. 9.
    Lencioni R. Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer. 2012;1:41–50.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Ke S, Ding X, Gao J, Gao K, Qian X, Cao B, et al. Solitary huge hepatocellular carcinomas 10 cm or larger may be completely ablated by repeated radiofrequency ablation combined with chemoembolization: initial experience with nine patients. Mol Med Rep. 2012;5:832–6.PubMedGoogle Scholar
  11. 11.
    Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther. 2006;23:129–35.CrossRefPubMedGoogle Scholar
  12. 12.
    Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 2000;58:293–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Lencioni R. New data supporting modified recist (mRECIST) for hepatocellular carcinoma. Clin Cancer Res. 2013;19:1312–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol. 2012;39:503–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Min YW, Lee JH, Gwak GY, Paik YH, Rhee PL, Koh KC, et al. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. J Gastroenterol Hepatol. 2014;29:1043–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Yoon HM, Kim JH, Kim EJ, Gwon DI, Ko GY, Ko HK. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. J Vasc Interv Radiol. 2013;24:1639–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, et al. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28:456–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Gao F, Gu YK, Fan WJ, Zhang L, Huang JH. Evaluation of transarterial chemoembolization combined with percutaneous ethanol ablation for large hepatocellular carcinoma. World J Gastroenterol. 2011;17:3145–50.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Yasuda S, Ito H, Yoshikawa M, Shinozaki M, Goto N, Fujimoto H, et al. Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy. Int J Oncol. 1999;15:467–73.PubMedGoogle Scholar
  20. 20.
    Cho JY, Paik YH, Park HC, Yu JI, Sohn W, Gwak GY, et al. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver Int. 2014;34:795–801.CrossRefPubMedGoogle Scholar
  21. 21.
    Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Konigsberg R, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263:590–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, et al. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24:307–15.CrossRefPubMedGoogle Scholar
  23. 23.
    Hsieh PM, Hung KC, Chen YS. Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol. 2009;15:4726–8.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13:60.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, et al. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg. 2014;259:532–42.CrossRefPubMedGoogle Scholar
  26. 26.
    Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de Beeck K et al. Chemoembolization for hepatocellular carcinoma: 1 month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology. 2014;270:747–57.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Tongchun Xue
    • 1
    • 2
  • Fan Le
    • 1
    • 2
  • Rongxin Chen
    • 1
    • 2
  • Xiaoying Xie
    • 1
    • 2
  • Lan Zhang
    • 1
    • 2
  • Ningling Ge
    • 1
    • 2
  • Yi Chen
    • 1
    • 2
  • Yanhong Wang
    • 1
    • 2
  • Boheng Zhang
    • 1
    • 2
    • 3
  • Shenglong Ye
    • 1
    • 2
  • Zhenggang Ren
    • 1
    • 2
  1. 1.Liver Cancer Institute, Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of EducationFudan UniversityShanghaiPeople’s Republic of China
  3. 3.Department of Medical Statistics, Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations